Skip to content
University of Colorado Anschutz Medical Campus CU Anschutz
  • Webmail
  • UCD Access
  • Canvas
  • Quick Links
 

Tools & Resources

  • Events Calendar
  • Newsroom
  • Strauss Health Sciences Library
  • Department A-Z Directory
  • Campus Directory
  • Leadership
  • Faculty & Staff Resources
  • Supporter & Alumni Resources
  • Student Resources
  • Campus Map
  • University Policies
  • Give Now

CU Campuses

  • CU Anschutz Medical Campus
  • CU Boulder
  • CU Colorado Springs
  • CU Denver
  • CU System
  • CU Online

CU Anschutz Medical Campus

  • School of Dental Medicine
  • Graduate School
  • School of Medicine
  • College of Nursing
  • Skaggs School of Pharmacy and Pharmaceutical Sciences
  • Colorado School of Public Health

CU Innovations

  • Innovator Resources
    • Funding & Resources
      • SPARK Colorado
      • Gates Grubstake Award
      • CU Healthcare Innovation Fund
      • Startup Toolbox
    • Innovation Information Guide
      • Protect Your Innovation
        • Invention Disclosure Process
        • Patent Your Innovation
        • Copyright Your Innovation
        • Trademark Your Innovation
      • Transfer Your Innovation
        • Start a Company
        • License Your Technology
        • Open Distribution
        • CU Translation Offices
      • Manage Your IP
        • Collaboration & IP
        • Sponsored Research & IP
        • Consulting & IP
        • Confidential Disclosure Agreements
        • Materials Transfer
      • Policies & Documents
      • Undergraduate Innovators
      • Liaisons Program
    • Healthcare Advisors
    • Form A Company
    • Innovation Hub
  • Partner With Us
    • Available Technologies
    • Licensing Technology from CU
    • Healthcare Partnerships
  • In The News
    • Newsroom
    • 2022 Annual Report
  • About Us
    • Meet the Team
    • Contact Us
    • Careers
  • COVID-19 Funding Opportunities
University Quick Links

New Cancer Test Uses Saliva to Detect Cancer


SummitDX develops HNKlear to test for head and neck cancers

By Stephanie Soh

Share this article

Send us your innovation news

Events Calendar

Head and neck cancer is the common term that encompasses a complex spectrum of diseases. The heading includes cancers that start in the nasal cavity, sinuses, lips, mouth, thyroid glands, salivary glands, pharynx, or larynx, yet methods for early detection of any have remained elusive. Fulfilling this need for improved diagnostic tools has become the mission of SummitDX, a University of Colorado Anschutz Medical Campus startup, and its molecular oncologist founder, Shi-Long Lu, MD, PhD.

SummitDX’s first product in development is called HNKlear, which tests for head and neck cancer recurrence following front-line treatment by detecting certain modifications to tumor DNA. What sets it apart is that HNKlear is a liquid biopsy test using samples from an obvious and abundant source: saliva. As Dr. Lu noted, saliva is a natural resource given its ready availability and the anatomic location of most head and neck cancers. The development of HNKlear drew on a number of Dr. Lu’s experiences, marrying his postdoc work on a noninvasive test for colorectal cancer, which evolved over time into the Cologuard® test from Exact Sciences, with his chosen specialization in head and neck squamous cell carcinoma. His familiarity with both laboratory and clinical research has pushed SummitDX to thoroughly explore the potential of HNKlear.


Article continues below


To bring the clinic and the laboratory together, Dr. Lu collaborated with Dr. John Song, a surgical oncologist and Director of Head and Neck Surgery at CU Anschutz. Dr. Song recognized the clinical need for monitoring cancer recurrence to choose the best therapies for the patient, and Dr. Lu recognized the potential for using microRNAs as a genetic biomarker and saliva as the sample. Together with their research team, they have devised a gamut of clinical utilities for HNKlear, ranging from use as a diagnostic tool to the ability to monitor progression and recurrence in patients.

More than just research and development has been occupying Dr. Lu’s time. SummitDX is the brainchild of over a year of after-work and behind-the-scenes planning and organization. Despite all of his scientific expertise, Dr. Lu found himself in a strange, new world, that of patents and business startups, in working to bring SummitDX to fruition and HNKlear to market. To help him make the leap to scientist entrepreneur, Dr. Lu has relied on both his network and the services offered by CU Innovations. 

Early funding for HNKlear came from the SPARK program, and since their introduction, Dr. Lu has looked to SPARK and CU Innovations for “help, training, and advocating for scientists and clinicians to become scientist entrepreneurs and know what the business world looks like.” Specifically, he participated in the SPARK program for step-by-step trainings in intellectual property rights, market research, business team formations, and investments. What Dr. Lu has found most beneficial of all has been the industry and business connections, in particular: Stan Lapidus, founder of Exact Sciences, serial entrepreneur, and now advisor to SummitDX; Bob Blomquist, healthcare industry executive and now CEO of SummitDX; Brian Harry, MD, PhD, clinical pathologist at CU Anschutz and now Chief Laboratory Officer; and Abby Wright, senior executive in reimbursement, and now advisor to SummitDX.

While they have received the first notice of allowance of HNKlear’s patent, filed with the assistance of SummitDX’s attorney and Heather Callahan, Portfolio Manager at CU Innovations, Dr. Lu is not resting on his laurels. The list of immediate objectives for HNKlear includes filing for international patent protection, validating clinical utilities beyond monitoring, developing its use as guidance for personalizing patient therapies, and collaborating with pharmaceutical companies on development and distribution. Their most ambitious target is to make HNKlear available as an early screening test in medical, and even dental, offices. Dr. Lu once thought the widespread accessibility of a test like HNKlear for early cancer screening would be a tremendous hurdle. These days, he’s heartened to see it becoming closer to reality as dental offices shift towards providing more general practitioner services.

Looking even further ahead, Dr. Lu has clear ambitions for SummitDX. Expansion plans include the development of tests based not just on saliva but also on other bodily fluids, such as sputum and cervical discharge, and the detection of not just head and neck squamous cell carcinoma but all types of squamous cell carcinomas, such as those in lung, esophagus, or cervical areas.

 

Innovator Bio

Shi-long

Shi-Long Lu, MD, PhD

Dr. Lu received his M.D. degree from China Medical University, and his Ph.D. Degree on Molecular Oncology from Tokyo Medical and Dental University. He completed his post-doctoral training in the Howard Hughes Medical Institute Lab at the Case Western Reserve University. He was an Assistant Professor of Otolaryngology, and Dermatology at the Oregon Health & Science University. He is currently an Assistant Professor of Otolaryngology, Dermatology, and Pathology at the University of Colorado Anschutz Medical Campus.

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


303-724-3720

Facebook Twitter YouTube LinkedIn
Healthcare Partners
  • UCHealth CARE Innovation Center
  • Children's Hospital Center for Innovation
  • Contact Us
  • Website Feedback
  • CU System
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Accreditation
  • Employment
  • Give Now
 

© 2022 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.

CMS Login

Webmail

UCD Access

Canvas

Opens in a new window Opens document in a new window